Search

Your search keyword '"Perri, Patrizia"' showing total 213 results

Search Constraints

Start Over You searched for: Author "Perri, Patrizia" Remove constraint Author: "Perri, Patrizia"
213 results on '"Perri, Patrizia"'

Search Results

1. From the identification of actionable molecular targets to the generation of faithful neuroblastoma patient-derived preclinical models

3. Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy

5. Quiescent hepatic stellate cells functionally contribute to the hepatic innate immune response via TLR3.

6. Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma

7. Abstract 2981: Anti-tumor activity of vobramitamab duocarmazine (MGC018), an investigational duocarmycin-based anti-B7-H3 antibody-drug conjugate (ADC), in preclinical neuroblastoma models

8. Abstract 3407: The italian personalized medicine program PREME for high-risk neuroblastoma

9. Data from ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis

10. Data from Therapeutic Targeting of TLR9 Inhibits Cell Growth and Induces Apoptosis in Neuroblastoma

11. Supplementary Figure 1 from Therapeutic Targeting of TLR9 Inhibits Cell Growth and Induces Apoptosis in Neuroblastoma

12. Supplementary Methods from Therapeutic Targeting of TLR9 Inhibits Cell Growth and Induces Apoptosis in Neuroblastoma

13. Supplementary Figure Legends from ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis

14. Supplementary Figures 1-19 from ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis

15. Therapeutic Targeting of ALK in Neuroblastoma: Experience of Italian Precision Medicine in Pediatric Oncology

17. Nucleolin expression has prognostic value in neuroblastoma patients

18. Abstract 1276: Nucleolin has prognostic value in neuroblastoma patients

21. MiR-486-5p Targets CD133+ Lung Cancer Stem Cells through the p85/AKT Pathway

22. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma

25. Cotargeting of miR‐126‐3p and miR‐221‐3p inhibits PIK3R2 and PTEN, reducing lung cancer growth and metastasis by blocking AKT and CXCR4 signalling

27. Additional file 5 of Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy

28. Additional file 3 of Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy

29. Additional file 2 of Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy

30. Additional file 4 of Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy

31. Additional file 9 of Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy

32. Additional file 7 of Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy

33. Additional file 6 of Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy

34. Bone Marrow Environment in Metastatic Neuroblastoma

35. Identification of ALK as a major familial neuroblastoma predisposition gene

38. Potential Role of miRNAs in the Acquisition of Chemoresistance in Neuroblastoma

41. Potential Onco-Suppressive Role of miR122 and miR144 in Uveal Melanoma through ADAM10 and C-Met Inhibition

42. Combined Replenishment of miR‐34a and let‐7b by Targeted Nanoparticles Inhibits Tumor Growth in Neuroblastoma Preclinical Models

43. Abstract A101: Nucleolin: A novel cell surface protein for neuroblastoma targeted therapy

44. A Proof-of-Concept for Epigenetic Therapy of Tissue Fibrosis: Inhibition of Liver Fibrosis Progression by 3-Deazaneplanocin A

49. Enhancement of Tumor Homing by Chemotherapy-Loaded Nanoparticles

Catalog

Books, media, physical & digital resources